caa a22 4500 445313080 CHVBK 20180317142637.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s11095-011-0523-5 doi (NATIONALLICENCE)springer-10.1007/s11095-011-0523-5 Immunogenicity of Therapeutic Proteins: The Use of Animal Models [Elektronische Daten] [Vera Brinks, Wim Jiskoot, Huub Schellekens] ABSTRACT: Immunogenicity of therapeutic proteins lowers patient well-being and drastically increases therapeutic costs. Preventing immunogenicity is an important issue to consider when developing novel therapeutic proteins and applying them in the clinic. Animal models are increasingly used to study immunogenicity of therapeutic proteins. They are employed as predictive tools to assess different aspects of immunogenicity during drug development and have become vital in studying the mechanisms underlying immunogenicity of therapeutic proteins. However, the use of animal models needs critical evaluation. Because of species differences, predictive value of such models is limited, and mechanistic studies can be restricted. This review addresses the suitability of animal models for immunogenicity prediction and summarizes the insights in immunogenicity that they have given so far. The Author(s), 2011 animal models nationallicence immunogenicity nationallicence therapeutic proteins nationallicence BLAST : basic local alignment search tool nationallicence CD : cluster of differentiation nationallicence HLA : human leucocyte antigen nationallicence MHC : major histocompatibility complex nationallicence PEG : polyethylene glycol nationallicence PLGA : poly(lactide-co-glycolide) nationallicence tPA : tissue plasminogen activator nationallicence Brinks Vera Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands aut Jiskoot Wim Division of Drug Delivery Technology Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands aut Schellekens Huub Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/10(2011-10-01), 2379-2385 0724-8741 28:10<2379 2011 28 11095 https://doi.org/10.1007/s11095-011-0523-5 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-011-0523-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brinks Vera Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Jiskoot Wim Division of Drug Delivery Technology Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands aut NATIONALLICENCE 700 1- Schellekens Huub Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/10(2011-10-01), 2379-2385 0724-8741 28:10<2379 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer